Apyx Medical (NASDAQ:APYX) Trading 3.2% Higher – Here’s What Happened

Apyx Medical Corporation (NASDAQ:APYX)’s share price traded up 3.2% on Tuesday . The stock traded as high as $3.95 and last traded at $3.84. 127,748 shares were traded during mid-day trading, a decline of 6% from the average session volume of 136,409 shares. The stock had previously closed at $3.72.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Roth Mkm assumed coverage on Apyx Medical in a report on Monday, December 15th. They issued a “buy” rating and a $6.00 price objective on the stock. Citizens Jmp upgraded Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research report on Wednesday, November 12th. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a report on Saturday, November 22nd. Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Apyx Medical Stock Performance

The company has a market cap of $146.84 million, a price-to-earnings ratio of -10.67 and a beta of 1.59. The firm’s 50 day simple moving average is $3.80 and its 200-day simple moving average is $3.17. The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44.

Institutional Investors Weigh In On Apyx Medical

A number of large investors have recently made changes to their positions in APYX. Kingsview Wealth Management LLC increased its holdings in shares of Apyx Medical by 9.4% in the second quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock valued at $431,000 after purchasing an additional 16,502 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in Apyx Medical in the 2nd quarter valued at $34,000. Nantahala Capital Management LLC increased its stake in shares of Apyx Medical by 2.5% in the 2nd quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after acquiring an additional 80,000 shares during the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical in the 2nd quarter worth $50,000. Finally, Salem Investment Counselors Inc. purchased a new position in shares of Apyx Medical during the 3rd quarter worth $97,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.